Pfizer PFE

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. FDA clears generic Dacogen

      Headlines

      Fri, 29 Aug 2014

      patients with myleodysplastic syndromes (bone marrow disorders). InnoPharma is in the process of being acquired by Pfizer ( PFE ). The deal was announced on July 16, 2014. Post your comment!

    2. New Morningstar Analyst Report for AbbVie Inc

      Stock Reports

      Fri, 29 Aug 2014

      penetrate these markets.The new competitive RA threat from Pfizer 's Xeljanz will not likely take much share from Humira ..... Humira. Key emerging competitive threats to Humira include Pfizer 's oral RA drug Xeljanz, cheaper generic versions of

    3. AbbVie: Growth Story Or Patent Expiration Nightmare?

      Headlines

      Thu, 28 Aug 2014

      manufacturer in the world, behind giants such as AstraZeneca (NYSE: AZN ), GlaxoSmithKline (NYSE: GSK ), and Pfizer (NYSE: PFE ). Humira Is AbbVie's Biggest Winner AbbVie generated 67% of its 2nd-quarter sales from its highly successful

    4. Pfizer C. diff vaccine candidate Fast Track'd

      Headlines

      Thu, 28 Aug 2014

      The FDA designates Pfizer 's (NYSE: PFE ) investigational Costridium difficile (C. difficile) vaccine candidate, PF-06425090, Fast Track. The Phase 2-stage product

    5. Gilead: Let's Make A Deal

      Headlines

      Thu, 28 Aug 2014

      Novo Nordisk, and Amgen. Gilead is rapidly approaching the market cap of the two largest US pure pharma companies, Pfizer and Merck, as well as the Swiss heavyweights, Roche and Novartis. Only JNJ, which is a diversified conglomerate with

    6. Growth Prospects Remain Strong For Pfizer

      Headlines

      Wed, 27 Aug 2014

      to show the same price movement - Pfizer (NYSE: PFE ) is one example as the stock has ..... 8%. Over the last two years, Pfizer has spun-off several of its business ..... strategy. These changes have allowed Pfizer to improve its cash position, which

    7. RPT-UPDATE 2- Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

      Headlines

      Tue, 26 Aug 2014

      Aug 26 (Reuters) - Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes...

    8. UPDATE 2- Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

      Headlines

      Tue, 26 Aug 2014

      Aug 26 (Reuters) - Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes...

    9. Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

      Headlines

      Tue, 26 Aug 2014

      Aug 26 (Reuters) - Pfizer Inc on Tuesday said it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.

    10. Pfizer and Merck team up in cancer study

      Headlines

      Tue, 26 Aug 2014

      Pfizer (NYSE: PFE ) and Merck (NYSE: MRK ) collaborate in a Phase 1b study evaluating ..... metastatic non-small cell lung cancer. The combination consists of Pfizer 's Xalkori ( crizotinib ) and Merck's investigational anti-PD

    « Prev12345Next »
    Content Partners